Monday, June 22, 2015 3:50:47 PM
It was the last 8k I was referring to. Just reread it now and I must apologize that there is no mention of restriction the shares. They speak of registering them.
The sale of those shares should not be a concern since he is over 10% and per your explanation he should be long.
OT, what is your opinion of them uplisting to a more prestigious exchange. Rk posted what is needed to qualify for uplisting to Nasdaq. Do you have any experience with any of your holdings doing this and what is the normal time frame? TIA, peace!
Recent MRKR News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/21/2025 05:15:11 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/17/2025 09:13:02 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 01/13/2025 09:05:17 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/10/2025 10:09:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2024 09:01:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/23/2024 09:40:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/23/2024 09:30:19 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 12/23/2024 09:30:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2024 01:21:17 PM
- Marker Therapeutics Announces $16.1 Million Private Placement • GlobeNewswire Inc. • 12/19/2024 01:06:43 PM
- Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma • GlobeNewswire Inc. • 12/19/2024 01:05:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/17/2024 12:10:42 PM
- Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer • GlobeNewswire Inc. • 12/17/2024 12:00:19 PM
- Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium • GlobeNewswire Inc. • 12/10/2024 01:30:44 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/06/2024 09:30:26 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/27/2024 09:27:23 PM
- Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit • GlobeNewswire Inc. • 11/26/2024 04:00:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2024 09:45:17 PM
- Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/14/2024 09:30:25 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2024 09:05:42 PM
- Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors • GlobeNewswire Inc. • 08/28/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:47:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:39:13 PM
UC Asset Announces Plan of Secondary Public Offering via Reg A • UCASU • Jan 23, 2025 9:30 AM
Luke Plants Featured in U.S. Department of the Interior Report to Congress on Strategic Review of National Orphan Well Program • ZEFIF • Jan 21, 2025 10:51 AM
North Bay Resources Acquires 70% Interest in the Bishop Gold Mill, Inyo County, California • NBRI • Jan 21, 2025 9:26 AM
HealthLynked Unveils Release of ARi: A Revolutionary AI-Powered Healthcare Assistant • HLYK • Jan 21, 2025 8:00 AM
Good Gaming Inc. Announces ViaOne Services' Intent to Purchase Up to 10% of Its Common Shares in the Open Market • GMER • Jan 16, 2025 8:30 AM
Avant Technologies and Ainnova Begin Implementing and Testing Advanced AI Algorithms for Early Detection of Additional Diseases • AVAI • Jan 16, 2025 8:00 AM